Combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof

A combination comprising a Mcl-1 inhibitor and a second anticancer agent, wherein the second anticancer agent is selected from anthracyclines, cytarabine and hypomethylating agents, and compositions and uses thereof.

Saved in:
Bibliographic Details
Main Authors Geneste, Olivier, Wei, Andrew, Moujalled, Donia, Pomilio, Giovanna, Maragno, Ana-Leticia
Format Patent
LanguageEnglish
Published 30.05.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A combination comprising a Mcl-1 inhibitor and a second anticancer agent, wherein the second anticancer agent is selected from anthracyclines, cytarabine and hypomethylating agents, and compositions and uses thereof.
Bibliography:Application Number: AU20180288520